The FDA has accepted the new drug application (NDA) for SH 201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers
For the treatment, including early rescue of Respiratory Distress Syndrome (RDS) or hyaline membrane disease in newborn babies. Prophylactic use in premature infants requiring intubation for stabilisation at risk from RDS or with evidence of surfactant deficiency.